Caxton Associates LLP Has $1.06 Million Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Caxton Associates LLP decreased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 63.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 15,163 shares of the company’s stock after selling 25,792 shares during the period. Caxton Associates LLP’s holdings in Tarsus Pharmaceuticals were worth $1,064,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rockefeller Capital Management L.P. lifted its stake in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares during the last quarter. Parallel Advisors LLC increased its position in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after buying an additional 291 shares during the last quarter. State of Wisconsin Investment Board raised its holdings in Tarsus Pharmaceuticals by 1.1% during the fourth quarter. State of Wisconsin Investment Board now owns 31,912 shares of the company’s stock valued at $2,613,000 after buying an additional 332 shares in the last quarter. Federated Hermes Inc. raised its holdings in Tarsus Pharmaceuticals by 0.6% during the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after buying an additional 339 shares in the last quarter. Finally, Valeo Financial Advisors LLC lifted its position in shares of Tarsus Pharmaceuticals by 11.1% in the fourth quarter. Valeo Financial Advisors LLC now owns 3,915 shares of the company’s stock worth $321,000 after buying an additional 392 shares during the last quarter. Institutional investors own 90.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Guggenheim decreased their price target on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a research note on Tuesday, July 21st. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. HC Wainwright restated a “buy” rating and issued a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $90.50.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $58.66 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25. The firm has a fifty day moving average price of $61.54 and a two-hundred day moving average price of $65.92. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -51.46 and a beta of 0.50.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.24. The company had revenue of $162.05 million for the quarter, compared to the consensus estimate of $149.60 million. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%. As a group, analysts forecast that Tarsus Pharmaceuticals, Inc. will post -1.04 earnings per share for the current year.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, Director William J. Phd Link sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.12, for a total value of $776,500.00. Following the sale, the director owned 106,786 shares of the company’s stock, valued at $6,633,546.32. This trade represents a 10.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Farrow sold 14,396 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $60.95, for a total value of $877,436.20. Following the completion of the transaction, the insider directly owned 56,801 shares in the company, valued at approximately $3,462,020.95. This represents a 20.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,850 shares of company stock worth $2,452,821 over the last quarter. 9.64% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.